Clinical Scorecard: Linking the Remnant Cholesterol-Inflammation Index to Major Adverse Cardiovascular Event Risk in Angina Patients Undergoing Percutaneous Coronary Intervention: A Retrospective Analysis

At a Glance

Key Highlights

• Study included 2,171 angina patients with a median follow-up of 36 months.
• Each standard deviation increase in RCII was associated with a 5% higher MACE risk.
• Moderate discriminatory ability of RCII for MACE risk was demonstrated with AUCs ranging from 0.739 to 0.786 over 30 months.
• RCII significantly associated with MACE risk across various subgroups including age, sex, and comorbidities.
• RCII may serve as a potential clinical biomarker for assessing MACE risk.

Guideline-Based Recommendations

Diagnosis

• Evaluate baseline RCII in patients with angina undergoing PCI.

Management

• Consider RCII as a potential biomarker for cardiovascular risk assessment.

Monitoring & Follow-up

• Monitor RCII levels to evaluate ongoing cardiovascular risk.

Risks

• Patients with elevated RCII may have increased risk of MACE.

Patient & Prescribing Data

Angina patients undergoing PCI.

Focus on managing both dyslipidemia and inflammation to reduce MACE risk.

Clinical Best Practices

• Incorporate RCII measurement in routine risk assessment for angina patients.
• Address both metabolic and inflammatory factors in cardiovascular risk management.

Related Resources & Content

• Study on MACE risk post-myocardial infarction
• ESC/EAS guidelines on LDL-C management
• Research on RC as a cardiovascular risk factor
• Prospective cohort study on hs-CRP and MACE